What form of B12 is used in the injection
This dual action promotes the reduction of existing fat stores while preventing the accumulation of new fat
Postoperative efficacy was categorized using the modified MacNab criteria as excellent, good, fair, or poor based on symptom disappearance, impact on daily life, and activity limitations
Patients should maintain adequate hydration and monitor their symptoms
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
Dispose of the needle and syringe: Carefully remove the needle from the injection site and dispose of the used needle and syringe in a puncture-resistant container
